Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2010-11-24
pubmed:abstractText
The objective was to determine the cost-effectiveness of treating anemic patients with chronic kidney disease (CKD) with erythropoiesis-stimulating agents (ESAs) to a low (9-10.9 g/dL), intermediate (11-12 g/dL), or high (> 12 g/dL) hemoglobin level target compared with a strategy of managing anemia without ESAs.
pubmed:grant
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1523-6838
pubmed:author
pubmed:copyrightInfo
Copyright © 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
56
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1050-61
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
An economic evaluation of erythropoiesis-stimulating agents in CKD.
pubmed:affiliation
Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada. braden.manns@albertahealthservices.ca
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Evaluation Studies